Scientists track experimental Drug's journey in healthy men
NCT ID NCT07479745
First seen Jun 25, 2026 · Last updated Aug 13, 2026 · Updated 3 times
Summary
This early-stage study gives 10 healthy men a single dose of GRT6019 with a radioactive tracer to see how the drug is broken down and eliminated. Researchers will measure radioactivity in urine and stool to understand the drug's metabolism. The study does not aim to treat any condition, but to gather essential data for future development.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- GRT6019 (also called Tegacorat or GRM-01) with a radioactive tracer
- What this could lead to
- If successful, this study will show how the body processes and eliminates GRT6019, which is needed before it can be tested as a potential treatment.
- What could go wrong
- This is a very early, small study in just 10 healthy men. It is not designed to test if the drug works or is safe for any disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
10 people
The number who actually took part.
- Started
-
Mar 2026
- Finished
-
Jun 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
30 to 65 years
- Sex
-
Male participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Healthy volunteers 2. Aged 30 to 65 years inclusive at the time of signing informed consent Exclusion Criteria: 1. Serious adverse reaction or serious hypersensitivity to any drug or formulation excipients 2. Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hay fever is allowed unless it is active 3. Presence or history of diseases or conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs 4. History of clinically significant cardiovascular, renal, hepatic, respiratory, particularly gastrointestinal (GI) disease, especially peptic ulceration, clinically significant GI bleeding, ulcerative colitis, Crohn's disease or irritable bowel syndrome, neurological or psychiatric disorder, or clinically significant dermatological disorder 5. History of GI surgery (with the exception of appendectomy or hernia repair unless it was performed within the previous 12 months)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy male volunteers are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Quotient Sciences
Nottingham, NG11 6JS, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.